SCHEMBL6520495

SCHEMBL6520495

Cc1cc(C[C@H](N)C(=O)O)cc(C)c1Oc1ccc2[nH]cc(S(=O)(=O)c3ccc(C(F)(F)F)cc3)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 11/20 0.46
THRA P10827 10/20 0.46
MAPT P10636 1/20 0.45
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
LTA4H P09960 1/20 0.41
PLA2G2A P14555 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 4/20 0.39
HTT P42858 2/20 0.39
RXFP1 Q9HBX9 1/20 0.38
TP53 P04637 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
GABRP O00591 1/20 0.38
GABRD O14764 1/20 0.38
ABCB11 O95342 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6516185 1.00 THRB (0.46) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6511286 0.92 THRB (0.49) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6514045 0.92 THRB (0.49) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6520698 0.91 THRB (0.41) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6515519 0.91 THRB (0.41) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6515786 0.91 THRB (0.41) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6512692 0.91 THRB (0.41) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6521706 0.91 SMN1; SMN2 (0.48) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6523587 0.91 SMN1; SMN2 (0.48) THRBTHRAMAPTMEN1KMT2A
SCHEMBL6514304 0.91 MAPT (0.56) THRBTHRAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032874-A1 Anticholesterol agents; arteriosclerosis BAYER AKTIENGESELLSCHAFT (DE) 2005-02-10 US disclosed
US-6794406-B2 FOR THERAPY AND PROPHYLAXIS OF ARTERIOSCLEROSIS AND HYPERCHOLESTEROLAEMIA BAYER AKTIENGESELLSCHAFT (DE) 2004-09-21 US disclosed
EP-1347959-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS Bayer Aktiengesellschaft (DE) 2003-10-01 EP disclosed
US-20030078288-A1 Indole derivatives BAYER AKTIENGESELLSCHAFT (DE) 2003-04-24 US disclosed
WO-2002051805-A1 INDOLE DERIVATIVES AS LIGANDS OF THYROID RECEPTORS BAYER AKTIENGESELLSCHAFT (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078288-A1 Indole derivatives IDO1, IDO2, TPH2 THRB 1772/4885THRA 2460/4885MAPT 839/4885
US-20050032874-A1 Anticholesterol agents; arteriosclerosis HMGCR, CYP46A1, EBP THRB 1835/4885THRA 1917/4885MAPT 3453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.